• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Upexi Appoints Brian Rudick, CFA as Chief Strategy Officer

    5/22/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email

    Rudick to oversee crypto strategy and visibility-related functions

    Rudick brings deep traditional finance and crypto expertise and network

    TAMPA, FL / ACCESS Newswire / May 22, 2025 / Upexi Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, has appointed Brian Rudick, CFA as Chief Strategy Officer. In this role, Rudick will oversee the Company's cryptocurrency strategy as well as its go-to-market, marketing, and investor relations functions to enhance the Company's cryptocurrency efforts and maximize visibility for the Company.

    Rudick brings deep expertise and connectivity in both traditional finance and crypto alike. Most recently, Rudick served as Head of Research for GSR, the largest digital asset market maker, where he demonstrated thought leadership externally and led internal business initiatives, including GSR's lead investment into Upexi's recent $100 million private placement. Prior to GSR, Rudick spent over a decade on Wall Street, primarily managing a long-short portfolio of bank stocks as a key member of financials-focused teams at Citadel, Balyasny, and Millennium. Rudick started his career at the Federal Reserve, where he conducted research as part of the monetary policy process. He holds a BSc from Duke University, an MBA from The University of Chicago, and is a CFA Charterholder.

    Allan Marshall, CEO of Upexi, commented, "Brian brings a wealth of knowledge as well as robust ties to both Wall Street and the cryptocurrency industry that will prove invaluable to our crypto strategy, capital raising efforts, and more. We are excited to have him aboard as he hones our crypto operations and amplifies our visibility amongst investors of all types."

    "With a comprehensive understanding of the determinants of value, financial analysis, and competitive strategy, and immense knowledge of both equities and cryptocurrencies, Brian is uniquely suited to propel Upexi to the next level. As the largest shareholder of Upexi and being intimately familiar with the quality and consistency of Brian's work, we couldn't be more happy for Upexi and sure of the immense value Brian will create for shareholders," stated Jakob Palmstierna, President of GSR.

    Brian Rudick, newly appointed Chief Strategy Officer, stated, "I am beyond excited to join Upexi as Chief Strategy Officer. With over a decade of experience covering balance sheet-based financial companies, I know firsthand the power of Upexi's treasury strategy. And with a business model underpinned by the leading smart contract blockchain in Solana and a clear and consistent strategy that resonates with both traditional finance and the crypto community, I look forward to joining the leading Solana treasury company and the journey that lies ahead."

    About Upexi, Inc.

    Upexi is a brand owner specializing in the development, manufacturing and distribution of consumer products. The Company has entered the Cryptocurrency industry and cash management of assets through a Cryptocurrency Portfolio. For more information on Upexi's treasury strategy and future developments, visit www.upexi.com.

    Follow CEO, Allan Marshall, on X - https://x.com/marshall_a22015

    Follow CSO, Brian Rudick, on X - https://x.com/thetinyant

    Forward Looking Statements

    This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. For example, the Company is using forward looking statements when it discusses the anticipated use of proceeds. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with business strategy, potential acquisitions, revenue guidance, product development, integration, and synergies of acquiring companies and personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward- looking statements. Although we believe that the beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

    Company Contact

    Andrew Norstrud, Chief Financial Officer
    Email: [email protected]
    Phone: (702) 332-5591

    Investor Relations Contact

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    Email: [email protected]
    Phone: (212) 896-1254

    SOURCE: Upexi



    View the original press release on ACCESS Newswire

    Get the next $UPXI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:26 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Salkind Gene bought $550,002 worth of shares (241,229 units at $2.28), increasing direct ownership by 195% to 365,127 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:17 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Williams Thomas Charles

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:45 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:26 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BitGo and Upexi Announce Strategic Partnership to Secure Digital Asset Treasury Holdings

      BitGo, the leading infrastructure provider of digital asset solutions, today announced a strategic partnership with Upexi Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space. Under this partnership, Upexi will leverage BitGo's secure custodial and over-the-counter (OTC) trading services to manage its growing digital asset portfolio. This move builds on Upexi's recent announcement that it has increased its Solana (SOL) treasury holdings to over 595,000 tokens, valued at approximately $100 million at current value, and has begun generating staking revenue as part of its broad

      5/13/25 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Regains Compliance with NASDAQ

      Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

      12/23/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split

      DALLAS, TX, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced that it has launched an investigation into potential stock manipulation related to and following its recent reverse stock split, which was effective as of October 16, 2024. This decision follows a comprehensive review of highly irregular trading patterns and an unprecedented increase in the number of shareholder accounts, factors that collectively raise concerns about potential stock manipulation. This investigation also follows a recent r

      12/4/24 7:00:00 AM ET
      $MGRX
      $UPXI
      Misc Health and Biotechnology Services
      Health Care
      Medicinal Chemicals and Botanical Products

    $UPXI
    SEC Filings

    See more
    • Upexi Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      5/23/25 5:00:13 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-1 filed by Upexi Inc.

      S-1 - UPEXI, INC. (0001775194) (Filer)

      5/22/25 5:04:41 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      5/16/25 5:00:13 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Financials

    Live finance-specific insights

    See more
    • Upexi Regains Compliance with NASDAQ

      Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

      12/23/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Reports Fiscal Second Quarter 2024 Financial Results

      TAMPA, FL / ACCESSWIRE / February 14, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today reported its financial results for the fiscal second quarter 2024 ending December 31, 2023."During the quarter we continued to focus on optimizing and streamlining our operations, investing in our higher margin Brand Products and generating positive Adjusted EBITDA. While revenue for the most recent fiscal second quarter decreased sequentially, the operating measures we took allowed us to increase gross profit margins to 38%, as compared to the prior fiscal first quarter of 31.8%. We also generated pos

      2/14/24 4:05:00 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi to Host Fiscal 2024 Second Quarter Financial Results Conference Call on February 14th at 4:30 PM ET

      TAMPA, FL / ACCESSWIRE / February 12, 2024 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Wednesday, February 14, 2024 at 4:30 p.m. ET, to discuss its financial results for the fiscal 2024 second quarter and provide a business update.Financial Results Conference CallEvent:Fiscal 2024 Second Quarter Financial Results Conference CallDate:Wednesday, February 14, 2024Time:4:30 p.m. Eastern TimeLive Call:1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)Webcast:https://ir.upexi.com/news-events/ir-calendarFor those unable to join the confe

      2/12/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      5/31/23 7:05:10 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:37:37 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

      SC 13G/A - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:36:56 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care